tobramycin therapy pulmonary infection patient cystic fibrosis six patient exacerbation chronic pulmonary infection association cystic fibrosis treated intramuscular tobramycin 5 mgkgday 3 divided dos eight treatment course lasted 9 30 day mean serum level 25 microgml 1 3 hour 02 microgml 7 12 8 hour dose tobramycin mean tobramycin concentration sputum 03 microgml eightytwo percent 66 pathogenic bacterial isolates sputum either pseudomonas sp 64 staphylococcus aureus 18 ninetyseven percent pseudomonas sp 83 percent staphylococcus aureus inhibited 31 microg tobramycin per ml organism isolated therapy observed become resistant tobramycin although 3 occasion colonization new resistant gramnegative bacillus occurred 6 8 course therapy patient showed clinical improvement elimination bacterial pathogen sputum rarely achieved necessary produce clinical improvement colonization resistant flora uncommon finding tobramycin side effect limited local discomfort injection site nausea vomiting